Disease · MONDO_0019469

T-cell large granular lymphocyte leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. T-cell large granular lymphocyte leukemia. Diseases, record MONDO_0019469. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019469

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: T-cell large granular lymphocyte leukemia; Open Targets
Open Targets ID: MONDO_0019469; Open Targets
Other names: LGLL, T gamma lymphoproliferative disorder, T-LGL, T-LGL leukaemia, T-LGL leukemia, T-cell LGL leukaemia, T-cell LGL leukemia, T-cell large gran. lymph. leuk., T-cell large granular lymphocytic leukaemia, T-cell large granular lymphocytic leukemia, Tgamma large granular lymphocyte leukaemia, Tgamma large granular lymphocyte leukemia, large cell granular lymphogenous leukaemia, large cell granular lymphogenous leukemia, large cell granular lymphoid leukaemia, large cell granular lymphoid leukemia, large granular lymphocytic leukemia, large granular lymphocytosis, leukemia, large granular LYMPHOCYTIC, malignant, proliferation of large granular lymphocytes; Open Targets
Disease Ontology: DOID:0050751; Disease Ontology
NCI Thesaurus: C4664; NCI Thesaurus
Orphanet: ORPHA:86872; Orphanet
Highest stage of its drugs: Phase 2/3, for 3 of its 15 drugs, from ClinicalTrials.gov; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2/3	ClinicalTrials.gov	5	5	5	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
THALIDOMIDE	CHEMBL468	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RESIMMUNE	CHEMBL4297555		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TIPIFARNIB	CHEMBL289228	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD3E	T-cell surface glycoprotein CD3 epsilon chain	1	T-cell surface glycoprotein CD3 epsilon chain binding agent	Phase 2	https://conductscience.org/library/genes/916	Drugs and targets
CD52	CAMPATH-1 antigen	1	CAMPATH-1 antigen inhibitor	Phase 2	https://conductscience.org/library/genes/1043	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2/3	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2/3	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2/3	https://conductscience.org/library/genes/1642	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2/3	https://conductscience.org/library/genes/1719	Drugs and targets
DNMT1	DNA (cytosine-5)-methyltransferase 1	1	DNA (cytosine-5)-methyltransferase 1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1786	Drugs and targets
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	1	DNA (cytosine-5)-methyltransferase 3A inhibitor	Phase 1/2	https://conductscience.org/library/genes/1788	Drugs and targets
EEF2	Elongation factor 2	1	Elongation factor 2 inhibitor	Phase 2	https://conductscience.org/library/genes/1938	Drugs and targets
FNTA	Protein farnesyltransferase	1	Protein farnesyltransferase inhibitor	Phase 2	https://conductscience.org/library/genes/2339	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00003910	Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia	Phase 2	59	2013-05-27	Leukemia	CYCLOPHOSPHAMIDE, METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00345345	Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia	Phase 2	29	2019-05-03	T-LGL Lymphoproliferative Disorders	ALEMTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01191749	Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)	Phase 2	7	2017-05-09	Leukemia	ALEMTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00363779	Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia	Phase 2	5	2012-07-06	Large Granular Lymphocytic Leukemia, LGL Leukemia	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT05475925	A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas	Phase 1/2	200		LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)	DIBOTATUG	Its record names the disease	ClinicalTrials.gov
NCT01976182	Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia	Phase 2	166		Large Granular Lymphocytes Leukemia	CYCLOPHOSPHAMIDE, METHOTREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02974647	Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma	Phase 2	83		Lymphoma	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT06530576	Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia	Phase 2	48		T-LGL Leukemia, NK-LGL Leukemia	METHOTREXATE, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT04453345	TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL	Phase 2/3	42		T-LGL Leukemia, Clpd-Nk	METHOTREXATE, PREDNISONE, THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00611208	A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)	Phase 2	32		T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungoides, Cutaneous T-cell Lymphoma (CTCL)	RESIMMUNE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Methotrexate vs Cyclophosphamide: serious adverse events	56 of 59	8 of 16	75	NCT00003910

Source Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25795722	RESULT	1	PubMed
19199905	RESULT	1	PubMed
40069155	DERIVED	1	PubMed
34653242	DERIVED	1	PubMed
26765645	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019469

GET https://conductscience.org/api/diseases/v1/MONDO_0019469/drugs

API reference For AI assistants